Theranos Withdraws FDA Emergency Clearance Request for Zika Test
Theranos decided to rescind its request for FDA emergency clearance of its Zika nucleic acid-amplification-based assay.
The diagnostic tool, dubbed minilab, is intended to collect and process small blood samples on a compact testing platform.
The company studied the product in 16 studies across categories, including chemistry, immunochemistry, hematology and molecular biology. — José Vasquez